Top Qs
Timeline
Chat
Perspective
Gilteritinib
Chemical compound From Wikipedia, the free encyclopedia
Remove ads
Gilteritinib, sold under the brand name Xospata, is an anti-cancer drug.[6]
Remove ads
Mechanism of action
Gilteritinib acts as an inhibitor of FLT3, hence it is a tyrosine kinase inhibitor.[7]
History
Gilteritinib was developed by Astellas Pharma.
In April 2018, Astellas filed a new drug application with the Food and Drug Administration for gilteritinib for the treatment of adult patients with FLT3 mutation–positive (both ITD and TKD[8]) relapsed or refractory acute myeloid leukemia (AML).[9]
In November 2018, the FDA approved gilteritinib for treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.[10][4]
Gilteritinib was granted orphan drug status by the U.S. FDA, the European Commission (EC) and the Japan Ministry of Health, Labor and Welfare, for some AML patients.[11]
Gilteritinib was approved for medical use in Australia in March 2020.[12]
Remove ads
References
Further reading
External links
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads